LANSOPRAZOLE, A NOVEL BENZIMIDAZOLE PROTON PUMP INHIBITOR, AND ITS RELATED-COMPOUNDS HAVE SELECTIVE ACTIVITY AGAINST HELICOBACTER-PYLORI

被引:277
作者
IWAHI, T [1 ]
SATOH, H [1 ]
NAKAO, M [1 ]
IWASAKI, T [1 ]
YAMAZAKI, T [1 ]
KUBO, K [1 ]
TAMURA, T [1 ]
IMADA, A [1 ]
机构
[1] HYOGO MED UNIV, DEPT BACTERIOL, NISHINOMIYA, HYOGO 663, JAPAN
关键词
D O I
10.1128/AAC.35.3.490
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The activities of various types of antiulcer agents against Helicobacter pylori (formerly called Campylobacter pylori) strains were determined by an agar dilution method. Among the compounds tested, two benzimidazole proton pump inhibitors, lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5-mu-g/ml, and fourfold more potent than that of omeprazole. A major metabolite and two acid-converted rearrangement products of lansoprazole also exhibited good activities comparable or superior to that of the parent compound. Exposure to lansoprazole of H. pylori growing in a liquid medium led to an extensive loss of viability without a reduction in culture turbidity and produced an aberrant bacterial morphology characterized by the irregular constriction of cells and the collapse of cell surface structures. The antibacterial activity of lansoprazole and its related compounds was selective against H. pylori; common aerobic and anaerobic bacteria and Campylobacter jejuni were not inhibited by 100-mu-g/ml.
引用
收藏
页码:490 / 496
页数:7
相关论文
共 39 条
[1]   RESPONSE OF CAMPYLOBACTER-PYLORIDIS TO ANTIBIOTICS, BISMUTH AND AN ACID-REDUCING AGENT INVITRO - AN ULTRASTRUCTURAL-STUDY [J].
ARMSTRONG, JA ;
WEE, SH ;
GOODWIN, CS ;
WILSON, DH .
JOURNAL OF MEDICAL MICROBIOLOGY, 1987, 24 (04) :343-350
[2]  
BIASCO G, 1989, LANCET, V2, P1403
[3]   HELICOBACTER-PYLORI AND THE PATHOGENESIS OF GASTRODUODENAL INFLAMMATION [J].
BLASER, MJ .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (04) :626-633
[4]  
EBERHARDT R, 1990, REV INFECT DIS, V12, pS115
[5]  
GLUPCZYNSKI Y, 1987, LANCET, V1, P1096
[6]   MICROBIOLOGICAL ASPECTS OF HELICOBACTER-PYLORI (CAMPYLOBACTER-PYLORI) [J].
GOODWIN, CS ;
ARMSTRONG, JA .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1990, 9 (01) :1-13
[7]   TRANSFER OF CAMPYLOBACTER-PYLORI AND CAMPYLOBACTER-MUSTELAE TO HELICOBACTER GEN-NOV AS HELICOBACTER-PYLORI COMB-NOV AND HELICOBACTER MUSTELAE COMB-NOV, RESPECTIVELY [J].
GOODWIN, CS ;
ARMSTRONG, JA ;
CHILVERS, T ;
PETERS, M ;
COLLINS, MD ;
SLY, L ;
MCCONNELL, W ;
HARPER, WES .
INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, 1989, 39 (04) :397-405
[8]   THE MINIMUM INHIBITORY AND BACTERICIDAL CONCENTRATIONS OF ANTIBIOTICS AND ANTIULCER AGENTS AGAINST CAMPYLOBACTER-PYLORIDIS [J].
GOODWIN, CS ;
BLAKE, P ;
BLINCOW, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 17 (03) :309-314
[9]   CAMPYLOBACTER-PYLORI AND PEPTIC-ULCER DISEASE [J].
GRAHAM, DY .
GASTROENTEROLOGY, 1989, 96 (02) :615-625
[10]   SUSCEPTIBILITY OF CAMPYLOBACTER-PYLORI TO MACROLIDES AND FLUOROQUINOLONES [J].
HARDY, DJ ;
HANSON, CW ;
HENSEY, DM ;
BEYER, JM ;
FERNANDES, PB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 (05) :631-636